Low level drug product API form analysis - Avalide tablet NIR quantitative method development and robustness challenges

Journal of Pharmaceutical and Biomedical Analysis

Volumn 89, Issue , 2014, Pages 268-275

  Pan, Duohai ^a   Crull, George ^a   Yin, Shawn ^a   Grosso, John ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Irbesartan; PLS; Polymorph; Spectroscopy; SsNMR

Indexed keywords

HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; IRBESARTAN;

ALGORITHM; ARTICLE; CALIBRATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMIDITY; HYPERTENSION; LIMIT OF DETECTION; NEAR INFRARED SPECTROSCOPY; PRIORITY JOURNAL; TABLET HARDNESS;

IRBESARTAN; PLS; POLYMORPH; SPECTROSCOPY; SSNMR;

BIPHENYL COMPOUNDS; CHEMISTRY, PHARMACEUTICAL; HUMIDITY; HYDROCHLOROTHIAZIDE; LIMIT OF DETECTION; PARTICLE SIZE; SPECTROSCOPY, NEAR-INFRARED; TABLETS; TETRAZOLES;

EID: 84889661171     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.11.011     Document Type: Article

References (39)

1. Byrn S.R., Pfeiffer R.R., Stowell J.G. Solid-State Chemistry of Drugs 1999, SSCI, West Lafayette, IN.
2. Polymorphism in Pharmaceutical Solids 1999, Marcel Dekker, New York. H.G. Brittain (Ed.).
3. Raw A.S., Furness M.S., Gill D.S., Adams R.C., Holcombe F.O., Yu L.X. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). Adv. Drug Deliv. Rev. 2004, 56:397-414.
4. Byrn S., Pfeiffer R., Ganey M., Hoiberg C., Poochikian G. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm. Res. 1995, 12:945-954.
5. Food and Drug Administration, Center for Drug Evaluation and Research Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information June, 2007, http://www.fda.gov/cder/guidance/index.htm.
6. Bauer J., Spanton S., Henry R., Quick J., Dziki W., Porter W., Morris J. Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. 2001, 18:859-866.
7. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Q6A. Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances October, 1995, http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
8. Harris R.K. Applications of solid-state NMR to pharmaceutical polymorphism and related matters. J. Pharm. Pharmacol. 2007, 59:225-239.
9. 13C CPMAS NMR spectroscopy. Int. J. Pharm. 2010, 394:18-25.
10. Vogt F.G. Evolution of solid-state NMR in pharmaceutical analysis. Future Med. Chem. 2010, 2:915-922.
11. Bugay D.E. Characterization of the solid-state: spectroscopic techniques. Adv. Drug Deliv. Rev. 2001, 48:43-65.
12. Wildfong P.L.D., Morley N.A., Moore M.D., Morris K.R. Quantitative determination of polymorphic composition in intact compacts by parallel-beam X-ray powder diffractometry II. Data correction for analysis of phase transformations as a function of pressure. J. Pharm. Biomed. Anal. 2005, 39:1-7.
13. Dash A.K., Khin-Khin A., Suryanarayanan R. X-ray powder diffractometric method for quantitation of crystalline drug in microparticulate systems. I. Microspheres. J. Pharm. Sci. 2002, 91:983-990.
14. Fix I., Steffens K.J. Quantifying low amorphous or crystalline amounts of alpha-lactose-monohydrate using X-ray powder diffraction, near-infrared spectroscopy, and differential scanning calorimetry. Drug Dev. Ind. Pharm. 2004, 30:513-523.
15. Suryanarayanan R., Herman C.S. Quantitative analysis of the active tablet ingredient by powder X-ray diffractometry. Pharm. Res. 1991, 8:393-399.
16. Moore M.D., Cogdill R.P., Wildfong P.L.D. Evaluation of chemometric algorithms in quantitative X-ray powder diffraction (XRPD) of intact multi-component consolidated samples. J. Pharm. Biomed. Anal. 2009, 49:619-626.
17. Rumondor A.C.F., Taylor L.S. Application of partial least-squares (PLS) modeling in quantifying drug crystallinity in amorphous solid dispersions. Int. J. Pharm. 2010, 398:155-160.
18. Stephenson G.A., Forbes R.A., Reutzel-Edens S.M. Characterization of the solid state: quantitative issues. Adv. Drug Deliv. Rev. 2001, 48:67-90.
19. Vankeirsbilck T., Vercauteren A., Baeyens W., Van d.W.G., Verpoort F., Vergote G., Remon J.P. Applications of Raman spectroscopy in pharmaceutical analysis. TrAC - Trends Anal. Chem. 2002, 21:869-877.
20. Koradia V., Chawla G., Bansal A.K. Qualitative and quantitative analysis of clopidogrel bisulphate polymorphs. Acta Pharm. 2004, 54:193-204.
21. Campbell R.S.N., Williams A.C., Grimsey I.M., Booth S.W. Quantitative analysis of mannitol polymorphs. FT-Raman spectroscopy. J. Pharm. Biomed. Anal. 2002, 28:1135-1147.
22. Pelletier M.J. Quantitative analysis using Raman spectrometry. Appl. Spectrosc. 2003, 57:20A-42A.
23. Xie Y., Tao W., Morrison H., Chiu R., Jona J., Fang J., Cauchon N. Quantitative determination of solid-state forms of a pharmaceutical development compound in drug substance and tablets. Int. J. Pharm. 2008, 362:29-36.
24. Roggo Y., Chalus P., Maurer L., Lema-Martinez C., Edmond A., Jent N. A review of near infrared spectroscopy and chemometrics in pharmaceutical technologies. J. Pharm. Biomed. Anal. 2007, 44:683-700.
25. Alcala M., Blanco M., Bautista M., Gonzalez J.M. On-line monitoring of a granulation process by NIR spectroscopy. J. Pharm. Sci. 2010, 99:336-345.
26. Rantanen J., Antikainen O., Mannermaa J.P., Yliruusi J. Use of the near-infrared reflectance method for measurement of moisture content during granulation. Pharm. Dev. Technol. 2000, 5:209-217.
27. Rasanen E., Rantanen J., Jorgensen A., Karjalainen M., Paakkari T., Yliruusi J. Novel identification of pseudopolymorphic changes of theophylline during wet granulation using near infrared spectroscopy. J. Pharm. Sci. 2001, 90:389-396.
28. Moes J.J., Ruijken M.M., Gout E., Frijlink H.W., Ugwoke M.I. Application of process analytical technology in tablet process development using NIR spectroscopy: blend uniformity, content uniformity and coating thickness measurements. Int. J. Pharm. 2008, 357:108-118.
29. Short S.M., Cogdill R.P., Wildfong P.L.D., Drennen J.K., Anderson C.A. A near-infrared spectroscopic investigation of relative density and crushing strength in four-component compacts. J. Pharm. Sci. 2009, 98:1095-1109.
30. Bocskei Z., Simon K., Rao R., Caron A., Rodger C.A., Bauer M. Irbesartan crystal form B. Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1998, C54:808-810.
31. Bauer M., Harris R.K., Rao R.C., Apperley D.C., Rodger C.A. NMR study of desmotropy in Irbesartan, a tetrazole-containing pharmaceutical compound. J. Chem. Soc., Perkin Trans. 1998, 2:475-482.
32. Garcia E., Hoff C., Veesler S. Dissolution and phase transition of pharmaceutical compounds. J. Cryst. Growth 2002, 237-239:2233-2239.
33. Blanco M., Peguero A. Influence of physical factors on the accuracy of calibration models for NIR spectroscopy. J. Pharm. Biomed. Anal. 2010, 52:59-65.
34. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH) Q2R1. Validation of analytical procedures: Text and Methodology November, 2005, http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
35. Alcala M., Leon J., Ropero J., Blanco M., Romanach R.J. Analysis of low content drug tablets by transmission near infrared spectroscopy: selection of calibration ranges according to multivariate detection and quantitation limits of PLS models. J. Pharm. Sci. 2008, 97:5318-5327.
36. Berntsson O., Burger T., Folestad S., Danielsson L.G., Kuhn J., Fricke J. Effective sample size in diffuse reflectance near-IR spectrometry. Anal. Chem. 1999, 71:617-623.
37. Pasikatan M.C., Steele J.L., Spillman C.K., Haque E. Near infrared reflectance spectroscopy for online particle size analysis of powders and ground materials. J. Near Infrared Spectrosc. 2001, 9:153-164.
38. Meza C.P., Santos M.A., Romanach R.J. Quantitation of drug content in a low dosage formulation by transmission near infrared spectroscopy. AAPS PharmSciTech 2006, 7:E29.
39. Chalus P., Roggo Y., Walter S., Ulmschneider M. Near-infrared determination of active substance content in intact low-dosage tablets. Talanta 2005, 66:1294-1302.